Takeda farms out cancer drug alisertib to Puma Biotech | pharmaphorum
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Is Puma Biotechnology a Buy? | The Motley Fool
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
10 Takeover Targets of 2018
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | Fierce Pharma
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Opinion: 5 biotech stocks that could be the next big winners - MarketWatch
